Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

Murch, 1991, Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease, Gut, 32, 913, 10.1136/gut.32.8.913

Murch, 1993, Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease, Gut, 34, 1705, 10.1136/gut.34.12.1705

Braegger, 1992, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation, Lancet, 339, 89, 10.1016/0140-6736(92)90999-J

Van Deventer, 1997, Tumour necrosis factor and Crohn's disease, Gut, 40, 443, 10.1136/gut.40.4.443

Sandborn, 1999, Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety, Inflamm Bowel Dis, 5, 119, 10.1097/00054725-199905000-00008

Smith, 1990, A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins, Science, 248, 1019, 10.1126/science.2160731

Loetscher, 1990, Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor, Cell, 61, 351, 10.1016/0092-8674(90)90815-V

Engelmann, 1989, A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity, J Biol Chem, 264, 11974, 10.1016/S0021-9258(18)80162-4

Olsson, 1989, Isolation and characterization of a tumor necrosis factor binding protein from urine, Eur J Haematol, 42, 270, 10.1111/j.1600-0609.1989.tb00111.x

Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502

Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804

Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X

Elliott, 1994, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis, Lancet, 344, 1105, 10.1016/S0140-6736(94)90628-9

Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0

Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202

Schaible, 2000, Long term safety of infliximab, Can J Gastroenterol, 14, 29C, 10.1155/2000/698523

Winter, 1993, Humanized antibodies, Immunol Today, 14, 243, 10.1016/0167-5699(93)90039-N

Mohler, 1993, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists, J Immunol, 151, 1548, 10.4049/jimmunol.151.3.1548

Moreland, 1996, Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis, J Rheumatol, 23, 1849

Moreland, 1997, Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, N Engl J Med, 337, 141, 10.1056/NEJM199707173370301

Moreland, 1999, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial, Ann Intern Med, 130, 478, 10.7326/0003-4819-130-6-199903160-00004

Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401

Bathon, 2000, A comparison of etanercept methotrexate in patients with early rheumatoid arthritis, J Med, 343, 1586

D'Haens, 2000, results of center pilot trial (abstr), Gastroenterology, 118, A656, 10.1016/S0016-5085(00)84762-9

Best, 1976, Development Crohn's disease activity index, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1

Irvine, 1994, Quality of life: a valid reliable measure of therapeutic efficacy in the treatment inflammatory bowel disease, Gastroenterology, 106, 287, 10.1016/0016-5085(94)90585-1

COSTART, 1995

Kavanaugh, 2000, Lipsky Chimeric anti-tumor necrosis factor-alpha monoclonal treatment of patients with rheumatoid arthritis receiving methotrexate therapy, J Rheumatol, 27, 841

Stack, 1997, Randomised controlled trial of CDP571 antibody to tumour necrosis factor-Crohn's disease, Lancet, 349, 521, 10.1016/S0140-6736(97)80083-9

Sandborn, 2001, An engineered human antibody TNF (CDP571) for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 1330, 10.1053/gast.2001.24042

Feagan, 2000, A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease (abstr), Gastroenterology, 118, A655, 10.1016/S0016-5085(00)84761-7

Korth-Bradley, 2000, Lebsack The pharmacokinetics of etanercept in healthy volunteers, Pharmacother, 34, 161, 10.1345/aph.19126